ATE382367T1 - Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern - Google Patents

Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern

Info

Publication number
ATE382367T1
ATE382367T1 AT03723930T AT03723930T ATE382367T1 AT E382367 T1 ATE382367 T1 AT E382367T1 AT 03723930 T AT03723930 T AT 03723930T AT 03723930 T AT03723930 T AT 03723930T AT E382367 T1 ATE382367 T1 AT E382367T1
Authority
AT
Austria
Prior art keywords
prediposition
markers
expression
type
treatment
Prior art date
Application number
AT03723930T
Other languages
English (en)
Inventor
Habib Zaghouani
Randal Gregg
Original Assignee
Univ Missouri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Missouri filed Critical Univ Missouri
Application granted granted Critical
Publication of ATE382367T1 publication Critical patent/ATE382367T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03723930T 2002-04-09 2003-04-08 Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern ATE382367T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37166302P 2002-04-09 2002-04-09

Publications (1)

Publication Number Publication Date
ATE382367T1 true ATE382367T1 (de) 2008-01-15

Family

ID=29250718

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03723930T ATE382367T1 (de) 2002-04-09 2003-04-08 Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern
AT07025199T ATE554787T1 (de) 2002-04-09 2003-04-08 Behandlung von typ-1-diabetes vor und nach der expression von prädispositionsmarkern

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07025199T ATE554787T1 (de) 2002-04-09 2003-04-08 Behandlung von typ-1-diabetes vor und nach der expression von prädispositionsmarkern

Country Status (6)

Country Link
EP (2) EP1499346B1 (de)
AT (2) ATE382367T1 (de)
AU (2) AU2003230830A1 (de)
DE (1) DE60318423T2 (de)
ES (1) ES2301794T3 (de)
WO (2) WO2003086286A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010248938B2 (en) * 2009-05-13 2014-12-11 Gliknik Inc. Methods of using immunoglobulin aggregates
EP3915384A1 (de) 2014-11-07 2021-12-01 DuPont Nutrition Biosciences ApS Beta-galaktosidase- und/oder transgalactosylierungsaktivität exprimierende rekombinante wirtszelle mit mangel an cellulase
RU2018124307A (ru) * 2015-12-04 2020-01-14 Новартис Аг Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции
DK3607097T3 (da) 2017-04-07 2023-09-18 Dupont Nutrition Biosci Aps Bacillus-værtsceller, der danner beta-galactosidaser og lactaser i fravær af p-nitrobenzylesterase-sideaktivitet

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737057B1 (en) 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US20030103967A1 (en) 1997-01-07 2003-06-05 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
IL136114A0 (en) * 1997-11-14 2001-05-20 Euro Celtique Sa Immunoglobulin molecules having a synthetic variable region and modified specificity
WO1999032136A1 (en) * 1997-12-23 1999-07-01 Alexion Pharmaceuticals, Inc. Chimeric proteins for the treatment of diabetes
CA2416656A1 (en) 2000-06-05 2002-04-04 University Of Tennessee Corporation Compositions and methods for the endocytic presentation of immunosuppressive factors
WO2002078612A2 (en) * 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production
CN108533209B (zh) 2018-04-02 2020-07-10 中国石油天然气股份有限公司 固井水泥的体积稳定性的确定装置和方法

Also Published As

Publication number Publication date
WO2003086286A2 (en) 2003-10-23
AU2003230830A8 (en) 2003-10-27
ATE554787T1 (de) 2012-05-15
AU2003230830A1 (en) 2003-10-27
AU2003223528A8 (en) 2003-10-27
AU2003223528A1 (en) 2003-10-27
EP1938834B1 (de) 2012-04-25
EP1499346B1 (de) 2008-01-02
DE60318423T2 (de) 2009-02-12
EP1938834A1 (de) 2008-07-02
ES2301794T3 (es) 2008-07-01
WO2003086286A3 (en) 2004-04-22
WO2003086296A2 (en) 2003-10-23
EP1499346A4 (de) 2005-12-07
WO2003086296A3 (en) 2004-02-26
EP1499346A2 (de) 2005-01-26
DE60318423D1 (de) 2008-02-14

Similar Documents

Publication Publication Date Title
GB0225474D0 (en) Therapeutic agents
GB0223038D0 (en) Therapeutic compounds
ATE316786T1 (de) Behandlung von mukositis
ATE427762T1 (de) Vorlage zur behandlung von hamorrhoiden
ATE487493T1 (de) Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungen
DE69317494D1 (de) Zusammensetzungen, die mono oder polyhydroxylierte Aminosäuren zur Behandlung des Insulinunabhängigen Diabetes Mellitus enthalten
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
FI962591A0 (fi) Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä
DE60100625D1 (de) Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina
DE69012261D1 (de) Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
DE69835594D1 (de) Zusammensetzungen zur behandlung von irds oder ards die 3-(calcopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamid und lungensurfactant enthalten
SE0102147D0 (sv) New methods
ATE203511T1 (de) Selektive beta3-adrenergische agonisten
ATE335501T1 (de) Mittel zur behandlung von allergischen oder überempfindlichkeitszuständen
ATE382367T1 (de) Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE517617T1 (de) Behandlung von parkinson erkrankung mit kape
DK1174131T3 (da) Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom
EP1435962A4 (de) Behandlung von diabetes vom typ 1
DE50012667D1 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen
DE60017786D1 (de) Zusammensetzung mit retinal und aldehyde mit pilzverhütender aktivität
DE60128130D1 (de) Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1499346

Country of ref document: EP